Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Vomiting 22Nausea 16Neoplasms 5Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Breast Neoplasms 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Ovarian Neoplasms 2Leukemia 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumours 1Sezary Syndrome 1Seminoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Papillomavirus Infections 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Therapeutics 5Mycophenolic Acid 5Cyclosporine 5Psychiatric Rehabilitation 4Peripheral Blood Stem Cell Transplantation 4midostaurin 3avapritinib 2Sunitinib 2Pentetic Acid 2Methotrexate 2Early Intervention, Educational 2Darbepoetin alfa 2Busulfan 2thymoglobulin 1ripretinib 1liposomal doxorubicin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1denileukin diftitox 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thiotepa 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Mast-Cell × Granisetron × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡